Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center
CancerInternal medicineSurgeryPathologyOncologyRandomized controlled trialClinical endpointPlaceboCarcinomaHepatocellular carcinomaSorafenibDiseaseGemcitabineCabozantinibIn patientPhases of clinical researchCancer researchClinical trialMedicineGastroenterology
374Publications
55H-index
8,740Citations
Publications 381
Newest
#7Byung Woog Kang (Kyungpook National University Hospital)H-Index: 19
#9Ji Sung Lee (UOU: University of Ulsan)H-Index: 5
Summary null null Background null The prognosis of patients with advanced biliary tract cancer who have progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and safety of second-line liposomal irinotecan plus fluorouracil and leucovorin in patients with metastatic biliary tract cancer that has progressed on gemcitabine plus cisplatin. null null null Methods null This multicentre, open-label, randomised, phase 2b (NIFTY) study was done at five academic institut...
Source
#1Robin Kate Kelley (UCSF: University of California, San Francisco)H-Index: 44
#2Rebecca A. Miksad (BMC: Boston Medical Center)H-Index: 29
Last. Ghassan K. Abou-Alfa (Cornell University)H-Index: 55
view all 14 authors...
Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafenib based on the phase 3 CELESTIAL trial (NCT01908426). Cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated HCC. Patients were randomised 2:1 to receive cabozantinib 60 mg or placebo...
Source
Summary null null Background null Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements occur in 10–16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2 alter...
Source
#1Jasmine H. Francis (Cornell University)H-Index: 25
#2James J. Harding (Cornell University)H-Index: 32
Last. Dean F. Bajorin (Cornell University)H-Index: 97
view all 15 authors...
Importance null Fibroblast growth factor receptor (FGFR) 1 to 4 inhibitors are approved by the US Food and Drug Administration and suppress the mitogen-activated protein kinase (MAPK) pathway, with a potential for treatment-related retinopathy. To date, implications of FGFR inhibitor-associated ocular toxic effects are poorly described. Therefore, more detailed clinical descriptions of this ocular toxic effect could help explain visual symptoms while receiving drug therapy. null Objective null T...
Source
#1Andrew X. Zhu (Harvard University)H-Index: 101
#2Teresa MacarullaH-Index: 38
Last. John Bridgewater (UCL: University College London)H-Index: 45
view all 27 authors...
Importance null Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placebo. null Objective null To report the final overall survival (OS) results from the ClarIDHy trial, which aimed to demonstrate the efficacy of ivosidenib (AG-120)—a first-in-class, oral, small-molecule inhibitor of mutant IDH...
Source
#1Tim F. GretenH-Index: 71
#2Ghassan K. Abou-Alfa (Cornell University)H-Index: 55
Last. Ahmed Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 32
view all 21 authors...
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunothera...
Source
#1Milind Javle (University of Texas MD Anderson Cancer Center)H-Index: 49
#2Mitesh J. Borad (Mayo Clinic)H-Index: 46
Last. Christopher Sweeney (Harvard University)H-Index: 80
view all 19 authors...
Summary null null Background null Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the activity of US Food and Drug Administration-approved therapies in non-indicated tumours with potentially actionable molecular alterations. In this study, we present an analysis of patients with metastatic biliary tract cancers with HER2 amplification, overexpression, or both treated with a dual anti-HER2 regime...
Source
#1James J. Harding (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 32
Last. Benjamin R. Tan (WashU: Washington University in St. Louis)H-Index: 31
view all 21 authors...
Background null Arginine starvation depletes the micronutrients required for DNA synthesis and interferes with both thymidylate synthetase activity and DNA repair pathways in preclinical models of hepatocellular carcinoma (HCC). Pegylated arginine deiminase (ADI-PEG 20), an arginine degrader, potentiates the cytotoxic activity of platinum and pyrimidine antimetabolites in HCC cellular and murine models. null Methods null This was a global, multicenter, open-label, single-arm, phase 2 trial of AD...
Source
Source
#8David P. Kelsen (Cornell University)H-Index: 44
Background null Patients with germline/somatic BRCA1/BRCA2 mutations (g/sBRCA1/2) comprise a distinct biologic subgroup of pancreas ductal adenocarcinoma (PDAC). null Methods null Institutional databases were queried to identify patients who had PDAC with g/sBRCA1/2. Demographics, clinicopathologic details, genomic data (annotation sBRCA1/2 according to a precision oncology knowledge base for somatic mutations), zygosity, and outcomes were abstracted. Overall survival (OS) was estimated using th...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.